Dexcom has moved to extend the wear time of its G7 continuous glucose monitor (CGM) by submitting a 15-day version to the FDA for approval.
Key Points
- Extended Wear Time: Dexcom's latest submission proposes extending the G7’s wear duration from 10 to 15 days, giving users five additional days of continuous monitoring without sensor changes.
- Competitive Alignment: The move to a 15-day wear time aligns the G7 with Dexcom's Stelo biosensor and makes Dexcom a stronger competitor against other CGM devices in the market.
- Commitment to Innovation: This submission reflects Dexcom’s proactive approach to enhancing CGM functionality, aiming to provide greater convenience and flexibility for users.
The G7 currently offers:
- Accuracy: Recognized as the most accurate CGM on the market.
- Size: 60% smaller than the previous model, enhancing comfort and discretion.
- Warm-up Time: 30-minute warm-up—the shortest available.
- Alerts: Customizable alerts for high and low glucose levels, including a predictive alert for low glucose.
- Compatibility: Syncs with compatible smart devices or a Dexcom receiver.
The submission of the 15-day G7 CGM demonstrates Dexcom’s efforts to stay competitive in the CGM market. Patients and healthcare providers will be watching closely, as the extended wear time will significantly improve the user experience for those relying on continuous glucose monitoring.
For more information, visit Drug Delivery Business.
